NO3009428T3 - - Google Patents
Info
- Publication number
- NO3009428T3 NO3009428T3 NO15189570A NO15189570A NO3009428T3 NO 3009428 T3 NO3009428 T3 NO 3009428T3 NO 15189570 A NO15189570 A NO 15189570A NO 15189570 A NO15189570 A NO 15189570A NO 3009428 T3 NO3009428 T3 NO 3009428T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009113936 | 2009-05-08 | ||
| EP10772177.1A EP2428508B9 (en) | 2009-05-08 | 2010-05-06 | Diamino heterocyclic carboxamide compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO3009428T3 true NO3009428T3 (no) | 2018-07-21 |
Family
ID=43050157
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO15189570A NO3009428T3 (no) | 2009-05-08 | 2010-05-06 | |
| NO2020001C NO2020001I1 (no) | 2009-05-08 | 2020-01-16 | Gilteritinib eller et salt derav |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2020001C NO2020001I1 (no) | 2009-05-08 | 2020-01-16 | Gilteritinib eller et salt derav |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US8969336B2 (no) |
| EP (2) | EP2428508B9 (no) |
| JP (1) | JP5364159B2 (no) |
| KR (1) | KR101614572B1 (no) |
| CN (1) | CN102421761B (no) |
| AU (1) | AU2010245545B2 (no) |
| BR (1) | BRPI1011838B8 (no) |
| CA (1) | CA2760061C (no) |
| CY (3) | CY1117546T1 (no) |
| DK (2) | DK2428508T3 (no) |
| ES (2) | ES2559230T3 (no) |
| FR (1) | FR20C1003I2 (no) |
| HK (1) | HK1219105A1 (no) |
| HR (2) | HRP20151435T8 (no) |
| HU (3) | HUE026647T2 (no) |
| IL (1) | IL216132A (no) |
| LT (2) | LT3009428T (no) |
| LU (1) | LUC00147I2 (no) |
| MX (1) | MX2011011875A (no) |
| NL (1) | NL301028I2 (no) |
| NO (2) | NO3009428T3 (no) |
| PL (2) | PL3009428T3 (no) |
| PT (2) | PT2428508E (no) |
| RS (2) | RS57045B1 (no) |
| SI (2) | SI2428508T1 (no) |
| SM (2) | SMT201800237T1 (no) |
| TW (1) | TWI484961B (no) |
| WO (1) | WO2010128659A1 (no) |
| ZA (1) | ZA201108642B (no) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120208824A1 (en) * | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
| NZ589315A (en) | 2008-04-16 | 2012-11-30 | Portola Pharm Inc | 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| EP3549934A1 (en) | 2008-06-27 | 2019-10-09 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| RU2735545C2 (ru) | 2010-05-20 | 2020-11-03 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
| DK2603081T3 (en) | 2010-08-10 | 2017-01-16 | Celgene Avilomics Res Inc | COLLECTED BY A BTK INHIBITOR |
| JP2014005206A (ja) * | 2010-10-22 | 2014-01-16 | Astellas Pharma Inc | アリールアミノヘテロ環カルボキサミド化合物 |
| US8975249B2 (en) | 2010-11-01 | 2015-03-10 | Celgene Avilomics Research, Inc. | Heterocyclic compounds and uses thereof |
| JP5956999B2 (ja) | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | ヘテロアリール化合物およびその使用 |
| WO2012061415A1 (en) * | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Oxypyrimidines as syk modulators |
| ES2665013T3 (es) | 2010-11-10 | 2018-04-24 | Celgene Car Llc | Inhibidores de EGFR selectivos de mutante y usos de los mismos |
| CN102285969B (zh) * | 2011-06-28 | 2013-06-19 | 山东大学 | N-1-取代哌啶-4-芳胺类衍生物及其制备方法与应用 |
| EP2748192B2 (en) | 2011-08-23 | 2022-04-20 | Foundation Medicine, Inc. | Kif5b-ret fusion molecules and uses thereof |
| AR088570A1 (es) | 2011-10-28 | 2014-06-18 | Celgene Avilomics Res Inc | Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton |
| KR102019530B1 (ko) * | 2011-11-23 | 2019-09-06 | 포톨라 파마슈티컬스, 인코포레이티드 | 피라진 키나아제 저해제 |
| ME02648B (me) | 2012-01-17 | 2017-06-20 | Astellas Pharma Inc | Jedinjenje pirazin karboksamida |
| MY169233A (en) | 2012-03-15 | 2019-03-19 | Celgene Car Llc | Solid forms of an epidermal growth factor receptor kinase inhibitor |
| TR201816244T4 (tr) | 2012-03-15 | 2018-11-21 | Celgene Car Llc | Epidermal büyüme faktörü reseptörü kinaz inhibitörü tuzları. |
| KR102156398B1 (ko) * | 2012-11-06 | 2020-09-15 | 상하이 포천 파마슈티컬 씨오 엘티디 | Ａｌｋ 키나아제 억제제 |
| EP2935226A4 (en) | 2012-12-21 | 2016-11-02 | Celgene Avilomics Res Inc | HETEROARYL COMPOUNDS AND USES THEREOF |
| CN105188371A (zh) | 2013-02-08 | 2015-12-23 | 西建阿维拉米斯研究公司 | Erk抑制剂及其用途 |
| US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
| WO2015039613A1 (zh) * | 2013-09-18 | 2015-03-26 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
| KR102314960B1 (ko) | 2013-10-11 | 2021-10-19 | 얀센 바이오파마, 인코퍼레이트. | 치환된 뉴클레오사이드, 뉴클레오타이드 및 이의 유사체 |
| MX2016005054A (es) * | 2013-10-21 | 2016-07-19 | Merck Patent Gmbh | Compuestos heteroarilo como inhibidores de tirosina cinasa de bruton (bkt) y usos de los mismos. |
| WO2015084998A1 (en) * | 2013-12-05 | 2015-06-11 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| WO2015106025A1 (en) | 2014-01-09 | 2015-07-16 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Substituted benzoxazine and related compounds |
| NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
| PT3103453T (pt) * | 2014-02-04 | 2020-05-06 | Astellas Pharma Inc | Composição medicinal compreendendo um composto de carboxamida heterocíclica diamina como ingrediente activo |
| CN104016977B (zh) * | 2014-06-13 | 2016-06-22 | 山东大学 | 一种取代噻二嗪二酮类衍生物及其制备方法与应用 |
| EP3179858B1 (en) | 2014-08-13 | 2019-05-15 | Celgene Car Llc | Forms and compositions of an erk inhibitor |
| EP3233808B1 (en) | 2014-12-16 | 2021-07-14 | Signal Pharmaceuticals, LLC | Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin |
| BR112017012795A2 (pt) | 2014-12-16 | 2018-01-02 | Signal Pharmaceuticals, Llc | Formulações de 2-(terc-butilamino)-4-((1r,3r,4r)-3- hidroxi-4-metilciclo-hexilamino)-pirimidina-5- carboxamida |
| CA2975260C (en) | 2015-01-29 | 2024-05-21 | Signal Pharmaceuticals Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| RS64070B1 (sr) | 2015-07-03 | 2023-04-28 | Astellas Pharma Inc | Stabilna farmaceutska kompozicija za oralnu administraciju |
| JP6816100B2 (ja) | 2015-07-16 | 2021-01-20 | アレイ バイオファーマ、インコーポレイテッド | ＲＥＴキナーゼ阻害物質としての置換ピラゾロ［１，５−ａ］ピリジン化合物 |
| CN105001096B (zh) * | 2015-07-21 | 2017-07-21 | 沈阳化工研究院有限公司 | 一种制备4‑氨基‑n‑烷基苄胺的方法 |
| EP3795553B1 (en) | 2015-07-24 | 2024-05-15 | Celgene Corporation | Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
| JP6859954B2 (ja) * | 2015-11-04 | 2021-04-14 | アステラス製薬株式会社 | ジアミノヘテロ環カルボキサミド化合物を有効成分とするがん免疫治療用、及び／又は、免疫活性化用医薬組成物 |
| US20190099413A1 (en) | 2016-02-26 | 2019-04-04 | Ono Pharmaceutical Co., Ltd. | Drug for cancer therapy characterized in that axl inhibitor and immune checkpoint inhibitor are administered in combination |
| CN106083821B (zh) * | 2016-06-22 | 2019-01-11 | 上海皓元生物医药科技有限公司 | 一种3，5-二取代-吡嗪-2-甲酰胺化合物的合成方法 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| CN110267960B (zh) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CA3062981A1 (en) | 2017-05-17 | 2018-11-22 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Flt3 inhibitors for improving pain treatments by opioids |
| CN109384774B (zh) * | 2017-08-11 | 2023-02-17 | 中国科学院上海药物研究所 | 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用 |
| US20200197385A1 (en) | 2017-08-23 | 2020-06-25 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for cancer containing axl inhibitor as active ingredient |
| US11826363B2 (en) | 2017-10-13 | 2023-11-28 | Ono Pharmaceutical Co., Ltd. | Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient |
| TW201932464A (zh) | 2018-01-18 | 2019-08-16 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物 |
| EP3740490A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| CA3087354C (en) | 2018-01-18 | 2023-01-03 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| WO2019184966A1 (zh) * | 2018-03-28 | 2019-10-03 | 深圳市塔吉瑞生物医药有限公司 | 取代的二氨基杂环甲酰胺化合物及包含该化合物的组合物及其用途 |
| CA3111984A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| JP7201800B2 (ja) * | 2018-09-30 | 2023-01-10 | メッドシャイン ディスカバリー インコーポレイテッド | Ｆｌｔ３およびａｘｌの阻害剤としての３，９－ジアザスピロ［５，５］ウンデカン系化合物 |
| RS66346B1 (sr) * | 2018-10-22 | 2025-01-31 | Alumis Inc | Inhibitori tyk2 i njihova upotreba |
| US20220127206A1 (en) | 2019-03-13 | 2022-04-28 | Otsuka Pharmaceutical Co., Ltd. | Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine |
| PL3949952T3 (pl) | 2019-04-03 | 2024-10-14 | Astellas Pharma Inc. | Kompozycja farmaceutyczna |
| WO2021197344A1 (zh) * | 2020-03-30 | 2021-10-07 | 南京明德新药研发有限公司 | 二氮杂螺吡喃化合物的晶型 |
| CN111423387B (zh) * | 2020-05-11 | 2022-03-08 | 苏州康纯医药科技有限公司 | 一种Gilteritinib关键中间体的制备方法 |
| WO2021244505A1 (zh) * | 2020-06-01 | 2021-12-09 | 微境生物医药科技(上海)有限公司 | 新型吡嗪化合物 |
| WO2022009235A1 (en) * | 2020-07-10 | 2022-01-13 | Msn Laboratories Private Limited, R&D Center | Process for the preparation of gilteritinib fumarate |
| CN113943288A (zh) * | 2020-07-17 | 2022-01-18 | 微境生物医药科技(上海)有限公司 | 5,6-二氢吡嗪并[2,3-c]异喹啉化合物 |
| CN112225703B (zh) * | 2020-09-28 | 2022-03-11 | 广州智睿医药科技有限公司 | 一种治疗或预防与lrrk2激酶或异常lrrk2突变激酶活性相关疾病的药物 |
| WO2022078305A1 (zh) * | 2020-10-12 | 2022-04-21 | 四川海思科制药有限公司 | 一种杂环衍生物及其在医药上的应用 |
| WO2023027966A1 (en) * | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
| WO2023129667A1 (en) * | 2021-12-30 | 2023-07-06 | Biomea Fusion, Inc. | Pyrazine compounds as inhibitors of flt3 |
| EP4493188A2 (en) * | 2022-03-14 | 2025-01-22 | Purdue Research Foundation | Spleen tyrosine kinase inhibitor, composition, and methods of use |
| WO2023225005A1 (en) * | 2022-05-17 | 2023-11-23 | Biomea Fusion, Inc. | Flt3 combination therapy for cancer and compositions therefor |
| CN115124590B (zh) * | 2022-07-05 | 2024-10-22 | 武汉大学中南医院 | 一种靶向降解flt3-itd突变蛋白的protac类化合物及其制备方法与应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60017898T2 (de) * | 1999-06-09 | 2006-01-12 | Yamanouchi Pharmaceutical Co., Ltd. | Neuartige heterocyclische carboxamidderivate |
| WO2000076980A1 (fr) * | 1999-06-10 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveaux derives heterocycliques azotes ou leurs sels |
| CN1665789A (zh) | 2002-06-28 | 2005-09-07 | 山之内制药株式会社 | 二氨基嘧啶酰胺衍生物 |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| JP2008013499A (ja) | 2006-07-06 | 2008-01-24 | Sankyo Co Ltd | ５−シアノニコチンアミド誘導体 |
| WO2008016660A2 (en) * | 2006-08-02 | 2008-02-07 | Xanthus Pharmaceuticals, Inc. | Imidazoacridine compounds for treating leukemias |
| WO2008024974A1 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Pyrimidine and pyrazine derivatives |
| EP1914240B1 (en) | 2006-10-11 | 2009-12-02 | Astellas Pharma Inc. | EML4-ALK fusion gene |
| CN101535276B (zh) | 2006-10-23 | 2013-08-28 | 赛福伦公司 | 作为ALK和c-MET抑制剂的2,4-二氨基嘧啶稠合双环衍生物 |
| CA2671744C (en) | 2006-12-08 | 2012-08-28 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| JP2010513406A (ja) | 2006-12-22 | 2010-04-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌治療のための細胞周期キナーゼ阻害剤としての２−［（フェニルアミノ）−ピリミジン−４−イルアミノ］−シクロペンタンカルボキサミド誘導体及び関連化合物 |
| TWI389893B (zh) * | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二（芳胺基）芳基化合物 |
| NZ582485A (en) | 2007-07-17 | 2012-05-25 | Rigel Pharmaceuticals Inc | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
| WO2009020990A1 (en) | 2007-08-08 | 2009-02-12 | Smithkline Beecham Corporation | 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d] pyrimidin-4-yl) amino] benzamide derivatives as igf-1r inhibitors for the treatment of cancer |
| AU2008296479A1 (en) | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
| WO2009040399A1 (en) | 2007-09-28 | 2009-04-02 | Nerviano Medical Sciences S.R.L. | Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors |
| US20090270418A1 (en) | 2008-01-09 | 2009-10-29 | Marianne Sloss | Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith |
| EP2271630B1 (en) | 2008-04-07 | 2016-03-23 | Novartis AG | Compounds and compositions as protein kinase inhibitors |
| CN102056925A (zh) | 2008-04-07 | 2011-05-11 | Irm责任有限公司 | 作为激酶抑制剂的化合物和组合物 |
| JP5802127B2 (ja) | 2008-04-16 | 2015-10-28 | ポートラ ファーマシューティカルズ， インコーポレイテッド | Ｓｙｋ又はｊａｋキナーゼ阻害剤としての２，６−ジアミノ−ピリミジン−５−イル−カルボキサミド類 |
| CN102066340B (zh) * | 2008-04-16 | 2014-05-14 | 波托拉医药品公司 | 作为syk或jak蛋白激酶抑制剂的2,6-二氨基-嘧啶-5-基甲酰胺类化合物 |
| AU2009248923B2 (en) | 2008-05-21 | 2015-01-29 | Takeda Pharmaceutical Company Limited | Phosphorous derivatives as kinase inhibitors |
-
2010
- 2010-05-06 JP JP2011512353A patent/JP5364159B2/ja active Active
- 2010-05-06 EP EP10772177.1A patent/EP2428508B9/en active Active
- 2010-05-06 RS RS20180358A patent/RS57045B1/sr unknown
- 2010-05-06 PT PT107721771T patent/PT2428508E/pt unknown
- 2010-05-06 SM SM20180237T patent/SMT201800237T1/it unknown
- 2010-05-06 SI SI201031107T patent/SI2428508T1/sl unknown
- 2010-05-06 PT PT151895703T patent/PT3009428T/pt unknown
- 2010-05-06 WO PCT/JP2010/057751 patent/WO2010128659A1/ja active Application Filing
- 2010-05-06 DK DK10772177.1T patent/DK2428508T3/en active
- 2010-05-06 HU HUE10772177A patent/HUE026647T2/en unknown
- 2010-05-06 ES ES10772177.1T patent/ES2559230T3/es active Active
- 2010-05-06 DK DK15189570.3T patent/DK3009428T3/en active
- 2010-05-06 ES ES15189570.3T patent/ES2667706T3/es active Active
- 2010-05-06 PL PL15189570T patent/PL3009428T3/pl unknown
- 2010-05-06 LT LTEP15189570.3T patent/LT3009428T/lt unknown
- 2010-05-06 SI SI201031651T patent/SI3009428T1/en unknown
- 2010-05-06 BR BRPI1011838A patent/BRPI1011838B8/pt active IP Right Grant
- 2010-05-06 US US13/266,164 patent/US8969336B2/en active Active
- 2010-05-06 TW TW099114522A patent/TWI484961B/zh active
- 2010-05-06 EP EP15189570.3A patent/EP3009428B1/en active Active
- 2010-05-06 MX MX2011011875A patent/MX2011011875A/es active IP Right Grant
- 2010-05-06 PL PL10772177T patent/PL2428508T3/pl unknown
- 2010-05-06 RS RS20160032A patent/RS54552B1/en unknown
- 2010-05-06 AU AU2010245545A patent/AU2010245545B2/en active Active
- 2010-05-06 CN CN201080020181.4A patent/CN102421761B/zh active Active
- 2010-05-06 CA CA2760061A patent/CA2760061C/en active Active
- 2010-05-06 NO NO15189570A patent/NO3009428T3/no unknown
- 2010-05-06 HU HUE15189570A patent/HUE038515T2/hu unknown
- 2010-05-06 KR KR1020117026122A patent/KR101614572B1/ko active IP Right Review Request
-
2011
- 2011-11-03 IL IL216132A patent/IL216132A/en active Protection Beyond IP Right Term
- 2011-11-24 ZA ZA2011/08642A patent/ZA201108642B/en unknown
-
2014
- 2014-08-29 US US14/472,959 patent/US9487491B2/en active Active
-
2015
- 2015-12-30 HR HRP20151435TT patent/HRP20151435T8/hr unknown
-
2016
- 2016-01-27 CY CY20161100072T patent/CY1117546T1/el unknown
- 2016-03-16 SM SM201600075T patent/SMT201600075B/xx unknown
- 2016-06-21 HK HK16107176.3A patent/HK1219105A1/zh unknown
-
2018
- 2018-03-01 HR HRP20180368TT patent/HRP20180368T1/hr unknown
- 2018-03-27 CY CY20181100350T patent/CY1120367T1/el unknown
-
2020
- 2020-01-16 NO NO2020001C patent/NO2020001I1/no unknown
- 2020-01-17 NL NL301028C patent/NL301028I2/nl unknown
- 2020-01-21 LT LTPA2020002C patent/LTC2428508I2/lt unknown
- 2020-01-22 CY CY2020004C patent/CY2020004I1/el unknown
- 2020-02-04 FR FR20C1003C patent/FR20C1003I2/fr active Active
- 2020-02-06 LU LU00147C patent/LUC00147I2/fr unknown
- 2020-02-20 HU HUS2000005C patent/HUS000511I2/hu unknown